Article: Spherix Signs Agreement to Conduct Phase 3 Clinical Trial and Topical Hedgehog Agonist Accelerates Wound Healing in Diabetes.

M2 PRESSWIRE-24 May 2006-US Equity Network: Spherix Signs Agreement to Conduct Phase 3 Clinical Trial and Topical Hedgehog Agonist Accelerates Wound Healing in Diabetes(C)1994-2006 M2 COMMUNICATIONS LTD

RDATE:24052005

City of Industry, CA - Diabetes research update provided by U.S. Equity News. Spherix Incorporated (Nasdaq: SPEX) has signed an agreement with GleneaglesCRC, a major clinical research and drug development company based in Singapore, to conduct its phase 3 clinical trial on the use of Naturlose as a treatment for type 2 diabetes. Gleneagles has a record for participating in U.S. FDA approved clinical trials. Curis, Inc. (NASDAQ: CRIS), a ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!